Final judgement favours TwinStrand in Guardant patent case
TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.
How this was made
The 30-second read
Why it matters
The $245 million judgment and ongoing 6% royalty on a large portion of Guardant's revenue represent a material financial hit, likely influencing its stock price and investor sentiment.
Market read
The judgment introduces a sizable liability for Guardant Health, affecting its valuation and raising broader IP risk concerns in the biotech sector.
What to watch
Potential for the royalty rate to be offset by future product innovations and market expansion.
Background
TwinStrand Biosciences, a private precision genomics firm, won a patent infringement lawsuit against Guardant Health, a publicly traded liquid biopsy company.
Ticker impact
Guardant Health was ordered to pay over $245 million in damages and ongoing royalties after a court ruled it infringed TwinStrand patents.
Short-term price decline expected; medium-term volatility as investors reassess earnings outlook.
The judgment imposes a significant financial burden and ongoing royalty payments, which directly affect Guardant's profitability.
Market effects
Highlights patent risk for precision genomics and liquid biopsy companies.
U.S. biotech sector may see heightened scrutiny on IP litigation.
Sets precedent for royalty calculations in biotech patent cases worldwide.
Counterpoint
Guardant could absorb the cost and maintain growth if it successfully appeals or negotiates licensing.
Key entities
- CompanyTwinStrand Biosciences
Private precision genomics company that holds Duplex Sequencing patents.
- CompanyGuardant Health Inc.
Public liquid biopsy company (NASDAQ: GH) found to infringe TwinStrand patents.
